Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain

Figure 4

Protection against infection with A/PR/8 virus. BALB/c mice () were immunized two times at 2-week intervals by i.n. administration with 10 μg of influenza 3M2eC protein with 10 μg of TCTA1T and TmCTA1T, or 2 μg of CT as an adjuvant. Control groups were immunized with PBS or TCTA1T alone. Mice were challenged i.n. with 10 LD₅₀ of A/PR/8 virus three weeks after the last immunization. Survival rate (a) and body weight (b) were monitored daily after the challenge. Data are representative of three separate experiments.

(a)

(b)